Citi maintains buy rating on Cogent with $15 price target, expects significant upside

From Financial Modeling Prep: 2025-06-30 15:12:00

Citi reiterates Buy rating and $15 price target on Cogent Communications (NASDAQ:CCOI) ahead of pivotal data expected in July from Phase 2 SUMMIT trial for bezuclastinib in NonAdvSM. Market undervaluing potential for bezuclastinib to outperform Ayvakit in efficacy and safety. Base case projects 50% upside with compelling risk/reward profile. Analysts on 30-day Upside Catalyst Watch for potential major revaluation.



Read more at Financial Modeling Prep:: Citi Reiterates Buy on Cogent, Sees Big Upside Ahe…